Replies to post #4457 on Cytodyn Inc (CYDY)

[Amatuer17]

You said "Also this idea of uplisting is great but if they uplist with a product that is this far from market.... Then they are just in for a fall."

I actually agree on this point.

My logic was - Dr P has approval to do r/s by end of Aug - so he might do r/s by then - but we may not get any better news by that time and it will push SP down maybe below $1 pre-split. Based on this scenario speculation I sold 1/3rd of my holding and will re-enter post Aug when the direction is clearer.

[Inoviorulez]

Yah but not for a product in phase 3. I can see a biotech that uplists to a higher exchange with a phase 2 struggling. Most that I have seen in phase 2 have not done so well. But CYDY is in a unique situation because they are already in phase 3.

While it may seem like a long wait, I estimate that results for one of the HIV trials should be done by June/July of 2017. That's one year from now which is doable. Could take a few more months longer depending upon enrollment though.

[5TOP]

No offense but, what are you talking about? Is your strategy here to make a play on sales???

...a product that is this far from market

We have two phase 3 drugs. If you want to see the largest return in the shortest amount of time NOW is the time to invest. Actually, if you are confident in the product approval, just before phase 2 results is really the time to invest.

Then they are just in for a fall.

Seriously? Based on what??? That we are so overvalued currently??? I and others, said it before ASM, this should be trading between $3-$5 in phase 3. SeeThruEquity has a given a $3.40 price target. And once we uplist we will have exposure to a massive amount of new money and institutional investors.